When people hear the term GLP‑1, they often think of medications used for diabetes or weight loss. But GLP‑1 is not just a medication trend. It is a natural hormone made in the small intestine that helps regulate insulin release, glucagon, digestion speed, appetite, and fullness after eating. GLP‑1 medications work by mimicking this hormone’s effects in the body.

This matters because many health conditions that appear separate on the surface may actually share deeper biological connections.

Endometriosis, PCOS (polycystic ovary syndrome), and psoriasis are usually treated by different specialists. A gynecologist may manage endometriosis, an endocrinologist or gynecologist may manage PCOS, and a dermatologist may treat psoriasis.

But the body does not organize itself by medical specialty.

Hormones, the immune system, metabolism, the gut, skin, and reproductive organs are constantly communicating. When that communication becomes disrupted, inflammation may show up in different places: pelvic pain, irregular periods, acne, weight changes, fatigue, or skin flares.

One important messenger in this larger conversation is GLP‑1.

Endometriosis

In endometriosis, the issue is not only misplaced uterine-like tissue. It is also an inflammatory environment. Pelvic immune activity may influence how lesions grow, behave, and cause pain. Researchers have found lower GLP‑1 levels in the pelvic fluid of people with endometriosis, along with signs of immune cell activation. This does not prove GLP‑1 causes endometriosis, but it does suggest that pelvic inflammation and metabolic signaling may be linked.

PCOS (polycystic ovary syndrome)

PCOS is often described as a hormone disorder, but for many patients, it is also a metabolic disorder. Insulin resistance can drive higher insulin levels, which may increase ovarian testosterone production. That can worsen irregular cycles, acne, hair growth, weight gain, and fertility challenges. Because GLP‑1 helps regulate insulin and appetite, GLP‑1 receptor medications are being studied and used in selected patients with PCOS, especially when obesity or insulin resistance is present. They are not a cure, but they may be useful as part of a broader treatment plan.

Psoriasis

In psoriasis, the inflammation appears on the surface of the skin; however, psoriasis is an immune-mediated inflammatory disease and is associated with higher risks of obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Some studies suggest GLP‑1 receptor medications may improve psoriasis severity, possibly through both weight-related and anti-inflammatory effects. Still, they should not replace standard psoriasis treatments such as topical medications, light therapy, systemic drugs, or biologics.

Shared themes across conditions

The real lesson is not that endometriosis, PCOS, and psoriasis are the same disease. They are not. The lesson is that they share overlapping themes: inflammation, immune activation, insulin resistance, gut signaling, and metabolic stress.

Patients often sense these connections before medicine formally names them. They know that their painful periods, skin flares, fatigue, acne, weight changes, and irregular cycles do not feel like separate problems. They feel like one body asking for help.

That is why a more integrated approach matters.

A patient with PCOS may need metabolic screening. A patient with psoriasis may need diabetes and cardiovascular risk assessment. A patient with endometriosis may benefit from future research into pelvic immune and metabolic pathways.

GLP‑1 is not a miracle explanation, and GLP‑1 medications are not right for everyone. They should only be considered with a qualified healthcare provider who understands the patient’s full medical history, fertility goals, medications, and risks.

But GLP‑1 offers an important reminder: the body is connected. A signal that begins in the gut may influence metabolism, hormones, inflammation, and immune function across multiple systems.

Better medicine begins when we stop treating symptoms as isolated events and start asking how the whole body is communicating.

References

1. Bendotti G, et al. “The anti-inflammatory and immunological properties of GLP‑1 receptor agonists.” Pharmacological Research, 2022.
2. Krasnyi AM, et al. “The Levels of Ghrelin, Glucagon, Visfatin and GLP‑1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis…” International Journal of Molecular Sciences, 2022.
3. Vrbikova J, et al. “Incretin levels in polycystic ovary syndrome.” European Journal of Endocrinology, 2008.
4. Teede HJ, et al. “Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” Journal of Clinical Endocrinology & Metabolism, 2023.
5. Ku SC, Chang HC. “Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis.” Journal der Deutschen Dermatologischen Gesellschaft, 2024.

---

Written by Dr. Shankar Kumar